This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|January 30, 2020
WuXi Biologics Announces Development of Neutralizing Antibodies for Novel Coronavirus
Author(s)BioPharm International Editors
WuXi’s R&D team will be developing and manufacturing 2019-nCoV-neutralizing antibodies at the company's four GMP facilities.
Advertisement
WuXi Biologics announced on Jan. 29, 2020 that it will be developing multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.
According to a company press release, WuXi’s R&D team will be developing and manufacturing 2019-nCoV-neutralizing antibodies at the company's four GMP facilities with a single batch bioreactor capacity ranging from 2000 to 12,000 liters. The first batch is expected to be produced in two months for preclinical toxicology studies and initial human clinical studies and is estimated to treat up to 80,000 patients.
"Confronted by this severe outbreak, WuXi Biologics has taken prompt actions to accelerate the development of multiple neutralizing antibodies for 2019-nCoV, based on our extensive biologics development and manufacturing experience in the fields of infectious diseases. Compared with the traditional timeline of 12 to 18 months, all studies from DNA to IND could hopefully be completed in 4-5 months while maintaining high quality. This way we can provide effective and timely interventions for the disease caused by 2019-nCoV," said Dr. Chris Chen, CEO of WuXi Biologics, in the press release. "Continuing in our mission of 'enabling global partners and benefiting patients worldwide', WuXi Biologics will actively work together with global and domestic biotechnology companies, hospitals, medical institutions, and other parties to win the battle against this infectious disease."
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5